 Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3Harish Shankaran, Yi Zhang, Yunbing Tan and Haluk Resat PLOS Computational Biology, 2013, vol. 9, issue 8, 1-15 Abstract: The HER/ErbB family of receptor tyrosine kinases drives critical responses in normal physiology and cancer, and the expression levels of the various HER receptors are critical determinants of clinical outcomes. HER activation is driven by the formation of various dimer complexes between members of this receptor family. The HER dimer types can have differential effects on downstream signaling and phenotypic outcomes. We constructed an integrated mathematical model of HER activation, and trafficking to quantitatively link receptor expression levels to dimerization and activation. We parameterized the model with a comprehensive set of HER phosphorylation and abundance data collected in a panel of human mammary epithelial cells expressing varying levels of EGFR/HER1, HER2 and HER3. Although parameter estimation yielded multiple solutions, predictions for dimer phosphorylation were in agreement with each other. We validated the model using experiments where pertuzumab was used to block HER2 dimerization. We used the model to predict HER dimerization and activation patterns in a panel of human mammary epithelial cells lines with known HER expression levels in response to stimulations with ligands EGF and HRG. Simulations over the range of expression levels seen in various cell lines indicate that: i) EGFR phosphorylation is driven by HER1-HER1 and HER1-HER2 dimers, and not HER1-HER3 dimers, ii) HER1-HER2 and HER2-HER3 dimers both contribute significantly to HER2 activation with the EGFR expression level determining the relative importance of these species, and iii) the HER2-HER3 dimer is largely responsible for HER3 activation. The model can be used to predict phosphorylated dimer levels for any given HER expression profile. This information in turn can be used to quantify the potencies of the various HER dimers, and can potentially inform personalized therapeutic approaches.Author Summary: A family of cell surface molecules called the HER receptor family plays important roles in normal physiology and cancer. This family has four members, HER1-4. These receptors convert signals received from the extracellular environment into cell decisions such as growth and survival – a process termed signal transduction. In particular, HER2 and HER3 are over-expressed in a number of tumors, and their expression levels are associated with abnormal growth and poor clinical prognosis. A key step in HER-mediated signal transduction is the formation of dimer complexes between members of this family. Different dimer types have different potencies for activating normal and aberrant responses. Prediction of the dimerization pattern for a given HER expression level may pave the way for personalized therapeutic approaches targeting specific dimers. Towards this end, we constructed a mathematical model for HER dimerization and activation. We determined unknown model parameters by analyzing HER activation data collected in a panel of human mammary epithelial cells that express different levels of the HER molecules. The model enables us to quantitatively link HER expression levels to receptor dimerization and activation. Further, the model can be used to support additional quantitative investigations into the basic biology of HER-mediated signal transduction. Date: 2013 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:plo:pcbi00:1003201 DOI: 10.1371/journal.pcbi.1003201 Access Statistics for this article More articles in PLOS Computational Biology from Public Library of Science |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.